Behçet's syndrome

Rheumatic Disease Clinics of North America

Volumn 39, Issue 2, 2013, Pages 245-261

  Hatemi, Gulen ^a   Yazici, Yusuf ^b   Yazici, Hasan ^a  

^a ISTANBUL UNIVERSITY   (Turkey)

^b NYU HOSPITAL FOR JOINT DISEASES   (United States)

Author keywords

Beh et's syndrome; Diagnosis; Disease mechanisms; Epidemiology; Eye involvement; Genetics; Management; Vascular involvement

Indexed keywords

ADALIMUMAB; ALPHA INTERFERON; AZAPROPAZONE; AZATHIOPRINE; CANAKINUMAB; COLCHICINE; CORTICOSTEROID; CYCLOPHOSPHAMIDE; CYCLOSPORIN A; DAPSONE; ETANERCEPT; GEVOKIZUMAB; GLUCOCORTICOID; IMMUNOSUPPRESSIVE AGENT; INFLIXIMAB; MESALAZINE; METHYLPREDNISOLONE; MINOCYCLINE; MYCOPHENOLIC ACID; NONSTEROID ANTIINFLAMMATORY AGENT; PENICILLIN DERIVATIVE; PREDNISOLONE; REBAMIPIDE; THALIDOMIDE; TOCILIZUMAB; TUMOR NECROSIS FACTOR ALPHA INHIBITOR;

ACNE; ARTHRITIS; BEHCET DISEASE; BONE MARROW SUPPRESSION; CEREBRAL SINUS THROMBOSIS; CLINICAL FEATURE; DEEP VEIN THROMBOSIS; DEPRESSION; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG MEGADOSE; ENTHESOPATHY; ERYTHEMA NODOSUM; FLU LIKE SYNDROME; GASTROINTESTINAL DISEASE; GENETIC ASSOCIATION; GENITAL ULCER; HEREDITY; HUMAN; LOW DRUG DOSE; MORTALITY; MOUTH ULCER; NEUROLOGIC DISEASE; NEUROTOXICITY; OPTIMAL DRUG DOSE; PATIENT COMPLIANCE; PREVALENCE; PRIORITY JOURNAL; PULMONARY ARTERY ANEURYSM; RETINA VASCULITIS; REVIEW; SINGLE DRUG DOSE; SKIN DEFECT; THERAPY RESISTANCE; THROMBOPHLEBITIS; UVEITIS; VEIN THROMBOSIS;

ANEURYSM; ASIA, WESTERN; BEHCET SYNDROME; EYE DISEASES; FEMALE; GENETIC PHENOMENA; HUMANS; MALE; PREVALENCE; PULMONARY ARTERY; THROMBOSIS; VASCULAR DISEASES;

EID: 84876713859     PISSN: 0889857X     EISSN: 15583163     Source Type: Journal    
DOI: 10.1016/j.rdc.2013.02.010     Document Type: Review

References (98)

1. Yurdakul S., Günaydin I., Tüzün Y., et al. The prevalence of Behçet's syndrome in a rural area in northern Turkey. J Rheumatol 1988, 15(5):820-822.
2. Azizlerli G., Köse A.A., Sarica R., et al. Prevalence of Behçet's disease in Istanbul, Turkey. Int J Dermatol 2003, 42(10):803-806.
3. Papoutsis N.G., Abdel-Naser M.B., Altenburg A., et al. Prevalence of Adamantiades-Behçet's disease in Germany and the municipality of Berlin: results of a nationwide survey. Clin Exp Rheumatol 2006, 24(5 Suppl 42):S125.
4. Seyahi E., Tahir Turanli E., Mangan M.S., et al. The prevalence of Behçet's syndrome, familial Mediterranean fever, HLA-B51 and MEFV gene mutations among ethnic Armenians living in Istanbul, Turkey. Clin Exp Rheumatol 2010, 28(4 Suppl 60):S67-S75.
5. O'Duffy J.D. Summary of international symposium on Behçet's disease. Istanbul, September 29-30, 1977. J Rheumatol 1978, 5:229-233.
6. Calamia K.T., Wilson F.C., Icen M., et al. Epidemiology and clinical characteristics of Behçet's disease in the US: a population-based study. Arthritis Rheum 2009, 61:600-604.
7. Yazici Y., Moses N. Clinical manifestations and ethnic background of patients with Behçet's syndrome in a US Cohort. Arthritis Rheum 2007, 56:S502.
8. Salvarani C., Pipitone N., Catanoso M.G., et al. Epidemiology and clinical course of Behçet's disease in the Reggio Emilia area of Northern Italy: a seventeen-year population-based study. Arthritis Rheum 2007, 57(1):171-178.
9. Kural-Seyahi E., Fresko I., Seyahi N., et al. The long-term mortality and morbidity of Behçet syndrome: a 2-decade outcome survey of 387 patients followed at a dedicated center. Medicine (Baltimore) 2003, 82:60-76.
10. Ambrose N.L., Haskard D.O. Differential diagnosis and management of Behçet syndrome. Nat Rev Rheumatol 2013, 9(2):79-89.
11. Yazici Y., Yurdakul S., Yazici H. Behçet's syndrome. Curr Rheumatol Rep 2010, 12(6):429-435.
12. Hamuryudan V., Er T., Seyahi E., et al. Pulmonary artery aneurysms in Behçet syndrome. Am J Med 2004, 117(11):867-870.
13. Seyahi E., Melikoglu M., Akman C., et al. Pulmonary artery involvement and associated lung disease in Behçet disease: a series of 47 patients. Medicine (Baltimore) 2012, 91(1):35-48.
14. Lakhanpal S., Tani K., Lie J.T., et al. Pathologic features of Behçet's syndrome: a review of Japanese autopsy registry data. Hum Pathol 1985, 16(8):790-795.
15. Desbois A.C., Wechsler B., Resche-Rigon M., et al. Immunosuppressants reduce venous thrombosis relapse in Behçet's disease. Arthritis Rheum 2012, 64(8):2753-2760.
16. Ahn J.K., Lee Y.S., Jeon C.H., et al. Treatment of venous thrombosis associated with Behçet's disease: immunosuppressive therapy alone versus immunosuppressive therapy plus anticoagulation. Clin Rheumatol 2008, 27(2):201-205.
17. Seyahi E., Baskurt M., Melikoglu M., et al. The estimated pulmonary artery pressure can be elevated in Behçet's syndrome. Respir Med 2011, 105(11):1739-1747.
18. Tunc R., Keyman E., Melikoglu M., et al. Target organ associations in Turkish patients with Behçet's disease: a cross sectional study by exploratory factor analysis. J Rheumatol 2002, 29(11):2393-2396.
19. Hatemi G., Bahar H., Uysal S., et al. The pustular skin lesions in Behçet's syndrome are not sterile. Ann Rheum Dis 2004, 63:1450-1452.
20. Hatemi G., Fresko I., Tascilar K., et al. Increased enthesopathy among Behçet's syndrome patients with acne and arthritis: an ultrasonography study. Arthritis Rheum 2008, 58:1539-1545.
21. Hatemi G., Fresko I., Yurdakul S., et al. Reply to letter by Priori et al commenting on whether Behçet's syndrome patients with acne and arthritis comprise a true subset. Arthritis Rheum 2010, 62:305-306.
22. Karaca M., Hatemi G., Sut N., et al. The papulopustular lesion/arthritis cluster of Behçet's syndrome also clusters in families. Rheumatology (Oxford) 2012, 51(6):1053-1060.
23. Melikoglu M., Ugurlu S., Tascilar K., et al. Large vessel involvement in Behçet's syndrome: a retrospective survey. Ann Rheum Dis 2008, 67(Suppl II):67.
24. Melikoglu M., Fresko I., Mat C., et al. Short-term trial of etanercept in Behçet's disease: a double blind, placebo controlled study. J Rheumatol 2005, 32(1):98-105.
25. Gül A., Tugal-Tutkun I., Dinarello C.A., et al. Interleukin-1β-regulating antibody XOMA 052 (gevokizumab) in the treatment of acute exacerbations of resistant uveitis of Behçet's disease: an open-label pilot study. Ann Rheum Dis 2012, 71(4):563-566.
26. Aktulga E., Altaç M., Müftüoglu A., et al. A double blind study of colchicine in Behçet's disease. Haematologica 1980, 65(3):399-402.
27. Yurdakul S., Mat C., Tüzün Y., et al. A double-blind trial of colchicine in Behçet's syndrome. Arthritis Rheum 2001, 44(11):2686-2692.
28. Mat C., Yurdakul S., Uysal S., et al. A double-blind trial of depot corticosteroids in Behçet's syndrome. Rheumatology (Oxford) 2006, 45(3):348-352.
29. Yazici H., Ugurlu S., Seyahi E. Behçet syndrome: is it one condition?. Clin Rev Allergy Immunol 2012, 43(3):275-280.
30. Bird Stewart J.A. Genetic analysis of families of patients with Behçet's syndrome: data incompatible with autosomal recessive inheritance. Ann Rheum Dis 1986, 45(4):265-268.
31. Molinari N., Koné Paut I., Manna R., et al. Identification of an autosomal recessive mode of inheritance in paediatric Behçet's families by segregation analysis. Am J Med Genet A 2003, 122A(2):115-118.
32. Seyahi E., Ozdogan H. Juvenile Behçet's syndrome. Behçet's syndrome 2010, 205-214. Springer, New York. Y. Yazici, H. Yazici (Eds.).
33. Gul A., Ohno S. Genetics of Behçet's disease. Behçet's syndrome 2010, 265-276. Springer, New York. Y. Yazici, H. Yazici (Eds.).
34. Masatlioglu S., Seyahi E., Tahir Turanli E., et al. A twin study in Behçet's syndrome. Clin Exp Rheumatol 2010, 28(4 Suppl 60):S62-S66.
35. Remmers E.F., Cosan F., Kirino Y., et al. Genome-wide association study identifies variants in the MHC class I, IL10, and IL23R-IL12RB2 regions associated with Behçet's disease. Nat Genet 2010, 42(8):698-702.
36. de Craen A.J., Posthuma D., Remarque E.J., et al. Heritability estimates of innate immunity: an extended twin study. Genes Immun 2005, 6:167-170.
37. Criteria for diagnosis of Behçet's disease. International Study Group for Behçet's Disease. Lancet 1990, 335(8697):1078-1080.
38. Cheon J.H., çelik A.F., Kim W.H. Behçet's disease: gastrointestinal involvement. Behçet's syndrome 2010, 165-189. Springer, New York. Y. Yazici, H. Yazici (Eds.).
39. Yazici H. A critical look at diagnostic criteria: time for a change?. Bull NYU Hosp Jt Dis 2011, 69(2):101-103.
40. Hatemi G., Silman A., Bang D., EULAR Expert Committee, et al. EULAR recommendations for the management of Behçet disease. Ann Rheum Dis 2008, 67(12):1656-1662.
41. Hatemi G., Silman A., Bang D., et al. Management of Behçet disease: a systematic literature review for the European League Against Rheumatism evidence-based recommendations for the management of Behçet disease. Ann Rheum Dis 2009, 68(10):1528-1534.
42. Alpsoy E., Er H., Durusoy C., et al. The use of sucralfate suspension in the treatment of oral and genital ulceration of Behçet disease: a randomized, placebo-controlled, double-blind study. Arch Dermatol 1999, 135:529-532.
43. Tasli L., Mat C., De Simone C., et al. Lactobacilli lozenges in the management of oral ulcers of Behçet's syndrome. Clin Exp Rheumatol 2006, 24(5 Suppl 42):S83-S86.
44. Karacayli U., Mumcu G., Simsek I., et al. The close association between dental and periodontal treatments and oral ulcer course in Behçet's disease: a prospective clinical study. J Oral Pathol Med 2009, 38(5):410-415.
45. Yazici H., Pazarli H., Barnes C.G., et al. A controlled trial of azathioprine in Behçet's syndrome. N Engl J Med 1990, 322:281-285.
46. Alpsoy E., Durusoy C., Yilmaz E., et al. Interferon alfa-2a in the treatment of Behçet disease: a randomized placebo-controlled and double-blind study. Arch Dermatol 2002, 138:467-471.
47. Hamuryudan V., Mat C., Saip S., et al. Thalidomide in the treatment of the mucocutaneous lesions of the Behçet syndrome. A randomized, double-blind, placebo-controlled trial. Ann Intern Med 1998, 128:443-450.
48. Arida A., Fragiadaki K., Giavri E., et al. Anti-TNF agents for Behçet's disease: analysis of published data on 369 patients. Semin Arthritis Rheum 2011, 41(1):61-70.
49. Mat C.M., Bang D., Melikoglu M. The mucocutaneous manifestations and pathergy reaction in Behçet's Disease. Behçet's syndrome 2010, 53-72. Springer, New York. Y. Yazici, H. Yazici (Eds.).
50. Diamantopoulos AP, Hatemi G. Lack of efficacy of tocilizumab in mucocutaneous Behçet's syndrome: report of 2 cases. Rheumatology (Oxford), in press.
51. Moral F., Hamuryudan V., Yurdakul S., et al. Inefficacy of azapropazone in the acute arthritis of Behçet's syndrome: a randomized, double blind, placebo controlled study. Clin Exp Rheumatol 1995, 13:493-495.
52. Hamuryudan V., Ozyazgan Y., Hizli N., et al. Azathioprine in Behçet's syndrome: effects on long-term prognosis. Arthritis Rheum 1997, 40:769-774.
53. Saadoun D., Wechsler B., Terrada C., et al. Azathioprine in severe uveitis of Behçet's disease. Arthritis Care Res (Hoboken) 2010, 62(12):1733-1738.
54. Masuda K., Nakajima A., Urayama A., et al. Double-masked trial of cyclosporin versus colchicine and long-term open study of cyclosporin in Behçet's disease. Lancet 1989, 1:1093-1096.
55. Kotter I., Vonthein R., Zierhut M., et al. Differential efficacy of human recombinant interferon-alpha2a on ocular and extraocular manifestations of Behçet disease: results of an open 4-center trial. Semin Arthritis Rheum 2004, 33:311-319.
56. Kötter I., Hamuryudan V., Oztürk Z.E., et al. Interferon therapy in rheumatic diseases: state-of-the-art 2010. Curr Opin Rheumatol 2010, 22(3):278-283.
57. Onal S., Kazokoglu H., Koc A., et al. Long-term efficacy and safety of low-dose and dose escalating interferon alfa-2a therapy in refractory Behçet uveitis. Arch Ophthalmol 2011, 129:288-294.
58. Keino H., Okada A.A., Watanabe T., et al. Decreased ocular inflammatory attacks and background retinal and disc vascular leakage in patients with Behçet disease on infliximab therapy. Br J Ophthalmol 2011, 95:1245-1250.
59. Olivieri I., Leccese P., D'Angelo S., et al. Efficacy of adalimumab in patients with Behçet's disease unsuccessfully treated with infliximab. Clin Exp Rheumatol 2011, 29(Suppl 67):S54-S57.
60. Markomichelakis N., Delicha E., Masselos S., et al. A single infliximab infusion vs corticosteroids for acute panuveitis attacks in Behçet's disease: a comparative 4-week study. Rheumatology (Oxford) 2011, 50:593-597.
61. Markomichelakis N., Delicha E., Masselos S., et al. Intravitreal infliximab for sight threatening relapsing uveitis in Behçet disease: a pilot study in 15 patients. Am J Ophthalmol 2012, 154:534-541.e1.
62. Ugurlu S., Ucar D., Seyahi E., et al. Canakinumab in a patient with juvenile Behçet's syndrome with refractory eye disease. Ann Rheum Dis 2012, 71(9):1589-1591.
63. Cantarini L., Vitale A., Borri M., et al. Successful use of canakinumab in a patient with resistant Behçet's disease. Clin Exp Rheumatol 2012, 30(3 Suppl 72):S115.
64. Hamuryudan V., Yurdakul S., Moral F., et al. Pulmonary arterial aneurysms in Behçet's syndrome: a report of 24 cases. Br J Rheumatol 1994, 33(1):48-51.
65. Adler S., Baumgartner I., Villiger P.M. Behçet's disease: successful treatment with infliximab in 7 patients with severe vascular manifestations. A retrospective analysis. Arthritis Care Res 2012, 64:607-611.
66. Schreiber B.E., Noor N., Juli C.F., et al. Resolution of Behçet's syndrome associated pulmonary arterial aneurysms with infliximab. Semin Arthritis Rheum 2011, 41:482-487.
67. Tuzun H., Seyahi E., Arslan C., et al. Management and prognosis of nonpulmonary large arterial disease in patients with Behçet disease. J Vasc Surg 2012, 55(1):157-163.
68. Tayer-Shifman O.E., Seyahi E., Nowatzky J., et al. Major vessel thrombosis in Behçet's disease: the dilemma of anticoagulant therapy-the approach of rheumatologists from different countries. Clin Exp Rheumatol 2012, 30(5):735-740.
69. Jung Y.S., Hong S.P., Kim T.I., et al. Long-term clinical outcomes and factors predictive of relapse after 5-aminosalicylate or sulfasalazine therapy in patients with intestinal Behçet disease. J Clin Gastroenterol 2012, 46:e38-e45.
70. Hatemi I., Hatemi G., Erzin Y., et al. Characteristics, treatment and outcome of gastrointestinal involvement of Behçet's syndrome: experience in a dedicated center. Ann Rheum Dis 2012, 71(Suppl 3):391.
71. Sayarlioglu M., Kotan M.C., Topcu N., et al. Treatment of recurrent perforating intestinal ulcers with thalidomide in Behçet's disease. Ann Pharmacother 2004, 38(5):808-811.
72. Maruyama Y., Hisamatsu T., Matsuoka K., et al. A case of intestinal Behçet's disease treated with infliximab monotherapy who successfully maintained clinical remission and complete mucosal healing for six years. Intern Med 2012, 51(16):2125-2129.
73. Shimizu Y., Takeda T., Matsumoto R., et al. Clinical efficacy of adalimumab for a postoperative marginal ulcer in gastrointestinal Behçet disease. Nihon Shokakibyo Gakkai Zasshi 2012, 109(5):774-780. [in Japanese].
74. Kurtuncu M., Tuzun E., Mutlu M., et al. Clinical patterns and course of neuro-Behçet's disease: analysis of 354 patients comparing cases presented before and after 1990. Clin Exp Rheumatol 2008, 26(4 Suppl 50):S17.
75. Shugaiv E., Tüzün E., Mutlu M., et al. Mycophenolate mofetil as a novel immunosuppressant in the treatment of neuro-Behçet's disease with parenchymal involvement: presentation of four cases. Clin Exp Rheumatol 2011, 29(4 Suppl 67):S64-S67.
76. Fasano A., D'Agostino M., Caldarola G., et al. Infliximab monotherapy in neuro-Behçet's disease: four year follow-up in a long-standing case resistant to conventional therapies. J Neuroimmunol 2011, 239(1-2):105-107.
77. Urbaniak P., Hasler P., Kretzschmar S. Refractory neuro-Behçet treated by tocilizumab: a case report. Clin Exp Rheumatol 2012, 30(3 Suppl 72):S73-S75.
78. Shapiro L.S., Farrell J., Haghighi A.B. Tocilizumab treatment for neuro-Behçet's disease, the first report. Clin Neurol Neurosurg 2012, 114(3):297-298.
79. Aguiar de Sousa D., Mestre T., Ferro J.M. Cerebral venous thrombosis in Behçet's disease: a systematic review. J Neurol 2011, 258(5):719-727.
80. Saadoun D., Wechsler B., Resche-Rigon M., et al. Cerebral venous thrombosis in Behçet's disease. Arthritis Rheum 2009, 61(4):518-526.
81. Kotake S., Higashi K., Yoshikawa K., et al. Central nervous system symptoms in patients with Behçet disease receiving cyclosporine therapy. Ophthalmology 1999, 106:586-589.
82. Kotter I., Gunaydin I., Batra M., et al. CNS involvement occurs more frequently in patients with Behçet's disease under cyclosporin A (CSA) than under other medications-results of a retrospective analysis of 117 cases. Clin Rheumatol 2006, 25:482-486.
83. Kato Y., Numaga J., Kato S., et al. Central nervous system symptoms in a population of Behçet's disease patients with refractory uveitis treated with cyclosporine A. Clin Experiment Ophthalmol 2001, 29:335-336.
84. Akman-Demir G., Ayranci O., Kurtuncu M., et al. Cyclosporine for Behçet's uveitis: is it associated with an increased risk of neurological involvement?. Clin Exp Rheumatol 2008, 26(4 Suppl 50):S84-S90.
85. Turkstra F., van Vugt R.M., Dijkmans B.A., et al. Results of a questionnaire on the treatment of patients with Behçet's syndrome: a trend for more intensive treatment. Clin Exp Rheumatol 2012, 30(3 Suppl 72):S10-S13.
86. Kurosawa M., Inaba Y., Nishibu A., et al. Nationwide epidemiological survey of Behçet's disease in 2003 in Japanese. Clinical Experimental Rheumatology 2004, 22(4 Suppl 34):S84.
87. Zhang Z., He F., Shi Y. Behcet's disease seen in China: analysis of 334 cases. Rheumatol Int 2012, [Epub ahead of print].
88. Davatchi F., Jamshidi A.R., Banihashemi A.T., et al. WHO-ILAR COPCORD Study (Stage 1, Urban Study) in Iran. J Rheumatol 2008, 35(7):1384.
89. Al-Rawi Z.S., Neda A.H. Prevalence of Behçet's disease among Iraqis. Adv Exp Med Biol 2003, 528:37-41.
90. Krause I., Yankevich A., Fraser A., et al. Prevalence and clinical aspects of Behcet's disease in the north of Israel. Clin Rheumatol 2007, 26(4):555-560.
91. Al dalaan A., Al Ballaa S., Al Sukati M., et al. The prevalence of Behçet's disease in Al-Qassim region of Saudi Arabia. Behçet's Disease 1997, 170-172. Pub Adhoua, Tunis. M. Hamza (Ed.).
92. Assaad Khalil S.H., Kamel F.A., Ismail E.A. Starting a regional registry for patients with Behçet's disease in North West Nile Delta region in Egypt. Behçet's Disease 1997, 173-176. Pub Adhoua, Tunis. M. Hamza (Ed.).
93. Crespo J., Ribeiro J., Jesus E., et al. Behçet's disease: particular features at the central zone of Portugal. Behçet's Disease: International Congress series 1037 1993, 207-210. Excerpta Medica, Amsterdam. B. Wechsler, P. Godeau (Eds.).
94. González-Gay M.A., García-Porrúa C., Brañas F., et al. Epidemiologic and clinical aspects of Behçet's disease in a defined area of Northwestern Spain, 1988-1997. J Rheumatol 2000, 27(3):703-707.
95. Mahr A., Belarbi L., Wechsler B., et al. Population-based prevalence study of Behçet's disease: differences by ethnic origin and low variation by age at immigration. Arthritis Rheum 2008, 58(12):3951-3959.
96. Chamberlain M.A. Behcet's syndrome in 32 patients in Yorkshire. Ann Rheum Dis 1977, 36(6):491-499.
97. Jankowski J., Crombie I., Jankowski R. Behçet's syndrome in Scotland. Postgrad Med J 1992, 68(801):566-570.
98. Ek L., Hedfors E. Behçet's disease: a review and a report of 12 cases from Sweden. Acta Derm Venereol 1993, 73(4):251-254.